• +1-646-491-9876
    • +91-20-67278686

    Search

    Bcl 2 Like Protein 1-Pipeline Review H2 2017

    Bcl 2 Like Protein 1-Pipeline Review H2 2017

    • Report Code ID: RW0001881472
    • Category Life Sciences
    • No. of Pages 29
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Pipeline Review H2 2017

    Summary

    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I Preclinical and Discovery stages are 1 1 and 1 respectively. Similarly the universities portfolio in Discovery stages comprises 2 molecules respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Small-Cell Lung Cancer Leukemias Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Solid Tumor.

    The latest report Bcl 2 Like Protein 1-Pipeline Review H2 2017 outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
    - The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Overview
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Companies Involved in Therapeutics Development
    AbbVie Inc
    Takeda Pharmaceutical Company Ltd
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Drug Profiles
    ABT-737-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APG-1252-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WEHI-539-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Dormant Products
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Discontinued Products
    Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)-Product Development Milestones
    Featured News & Press Releases
    Apr 22 2013 Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539
    May 16 2005 Abbott Data Published In Nature Reveals A Promising New Approach In Cancer.
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by AbbVie Inc H2 2017
    Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Dormant Products H2 2017 (Contd..2) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    AbbVie Inc
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bcl-2-like-protein-1-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments